INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss

Financial Results Analysis

INMUNE BIO INC (NASDAQ:INMB) reported a narrower-than-expected loss for the third quarter of 2025. The clinical-stage biotechnology company announced a non-GAAP earnings per share (EPS) of -$0.24, which surpassed the analyst consensus estimate of -$0.3315. The company reported no revenue for the quarter, which was in line with analyst expectations of $0.0, as the firm remains in the clinical development phase for its immunology-focused therapies.

Market Reaction

The market responded positively to the earnings beat in after-hours trading. The stock demonstrated significant upward momentum following the release, a reaction that appears to be directly tied to the better-than-anticipated EPS figure. This immediate price action suggests investor relief and optimism regarding the company's ability to manage its financial burn rate more effectively than projected.

• After-market performance: +1.73%
• Last week's performance: +2.25%
• Last month's performance: -14.55%

The strong after-hours move contrasts with the stock's performance over the past month, which had seen a notable decline. This indicates that the quarterly results may have alleviated some of the recent negative sentiment surrounding the stock.

Business Update and Pipeline Focus

The core of the press release centered on a business update for INmune Bio, which is developing treatments that harness the patient's innate immune system. As a pre-revenue company, the financial results are secondary to the progress of its clinical pipeline. The update highlighted the company's focus on its three main platforms:

• The Dominant-Negative TNF platform, which is in clinical trials for Alzheimer's disease and treatment-resistant depression.
• The INKmune Natural Killer Cell Priming Platform for cancer.
• The CORDStrom platform involving mesenchymal stem cells.

The company announced it would host a conference call to discuss these results and provide further details on its clinical development programs. The absence of a specific financial outlook in the press release is typical for a company at this stage, as its value is primarily driven by clinical milestones rather than near-term revenue forecasts.

Forward-Looking Estimates

Looking ahead, analyst estimates reflect the ongoing clinical-stage nature of INmune Bio's business. For the fourth quarter of 2025, the consensus estimates project an EPS of -$0.33 and no revenue. For the full 2025 fiscal year, analysts are estimating an EPS of -$1.59. It is important to note that the estimated sales figure of $51,000 for the full year represents a nominal amount and does not signify the commencement of material commercial operations. The company's financial performance will continue to be measured by its clinical progress and its management of operating expenses.

For a detailed breakdown of historical earnings and future analyst estimates for INMUNE BIO INC, you can review the data here.

Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an offer to solicit any transaction. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.